Suppr超能文献

人类免疫缺陷病毒相关消瘦的单药/联合治疗

Single-agent/combination therapy of human immunodeficiency virus-related wasting.

作者信息

Wanke C

机构信息

Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.

出版信息

Semin Oncol. 1998 Apr;25(2 Suppl 6):98-103.

PMID:9625391
Abstract

Weight loss and wasting are significant contributors to morbidity in patients infected with the human immunodeficiency virus (HIV). The approach to the patient with HIV and weight loss needs to be proactive and comprehensive, as early intervention may be beneficial and the weight loss may be multifactorial. Evaluation for weight loss needs to be directed at any apparent contributing cause and can include dietary evaluation, treatment of intercurrent complicating infections or malignancies, and maximization of HIV therapy. Some patients will also benefit from an evaluation of the gastrointestinal tract to document malabsorption and/or opportunistic enteric infections. It is also prudent to evaluate testosterone levels in male patients. Interventions in the patient who is not able to take in sufficient calories should include dietary advice and/or nutritional supplements, as well as the use of appetite stimulants. Megace (Bristol-Myers Squibb, Princeton, NJ) has been shown to effectively increase appetite, oral intake, and body weight. For the patient with malabsorption and/or diarrhea, treatment of enteric infections should be attempted. These patients may benefit from the replacement of some dietary fat with medium-chain triglycerides, either in a nutritional product or to replace cooking oils. Other patients may benefit from the use of anabolic agents such as growth hormone, nandrolone, testosterone, or oxandrolone, which are all effective at increasing lean body mass. For select patients, agents such as thalidomide might be of benefit, although its mechanism of action is not clear. There are few data from prospective, controlled trials of combinations of these agents, but these studies are underway. It is likely that the optimal interventions for patients will be combinations of agents to improve oral intake and add lean body mass, which will permit a reduction in morbidity from weight loss and an improvement in quality of life for the HIV-infected patient.

摘要

体重减轻和消瘦是感染人类免疫缺陷病毒(HIV)患者发病的重要因素。对于HIV感染且体重减轻的患者,治疗方法需要积极且全面,因为早期干预可能有益,且体重减轻可能是多因素导致的。对体重减轻的评估需要针对任何明显的促成因素,可包括饮食评估、治疗并发的复杂感染或恶性肿瘤,以及优化HIV治疗。一些患者还将受益于胃肠道评估,以确定是否存在吸收不良和/或机会性肠道感染。评估男性患者的睾酮水平也是明智之举。对于无法摄入足够热量的患者,干预措施应包括饮食建议和/或营养补充剂,以及使用食欲刺激剂。Megace(百时美施贵宝公司,新泽西州普林斯顿)已被证明能有效增加食欲、口服摄入量和体重。对于存在吸收不良和/或腹泻的患者,应尝试治疗肠道感染。这些患者可能会从用中链甘油三酯替代部分膳食脂肪中获益,可通过营养产品或替代食用油来实现。其他患者可能会受益于使用合成代谢药物,如生长激素、诺龙、睾酮或氧雄龙,这些药物都能有效增加瘦体重。对于特定患者,沙利度胺等药物可能有益,尽管其作用机制尚不清楚。关于这些药物联合使用的前瞻性对照试验数据很少,但此类研究正在进行中。对于患者而言,最佳干预措施可能是联合使用多种药物,以改善口服摄入量并增加瘦体重,从而降低体重减轻导致的发病率,提高HIV感染患者的生活质量。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验